Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis Alberto Diaz, Alberto Bardelli · Journal of Clinical Oncology · 2014
Genotyping tumor tissue in search of somatic genetic alterations for actionable information has become routine practice in clinical oncology. Although these sequence alterations are highly informative, sampling tumor tissue has significant inherent limitations; tumor tissue is a single snapshot in time, is subject to selection bias resulting from tumor heterogeneity, and can be difficult to obtain. Cell-free fragments of DNA are shed into the bloodstream by cells undergoing apoptosis or necrosis, and the load of circulating cell-free DNA (cfDNA) correlates with tumor staging and prognosis. Moreover, recent advances in the sensitivity and accuracy of DNA analysis have allowed for genotyping of cfDNA for somatic genomic alterations found in tumors. The ability to detect and quantify tumor mutations has proven effective in tracking tumor dynamics in real time as well as serving as a liquid biopsy that can be used for a variety of clinical and investigational applications not previously possible.
Cited by 2,205 works. doi:10.1200/jco.2012.45.2011
Authors
References
- Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
- Cancer Genome Landscapes
- Presence of fetal DNA in maternal plasma and serum
- Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations
- Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
- Digital PCR
- Circulating mutant DNA to assess tumor dynamics